Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALIM logo

Alimera Sciences Inc (ALIM)ALIM

Upturn stock ratingUpturn stock rating
Alimera Sciences Inc
$5.54
Delayed price
Profit since last BUY-5.98%
SELL
upturn advisory
SELL since 4 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

09/13/2024: ALIM (1-star) is a SELL. SELL since 4 days. Profits (-5.98%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: SELL
Historic Profit: -36.78%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 47
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 09/13/2024
Type: Stock
Today’s Advisory: SELL
Historic Profit: -36.78%
Avg. Invested days: 47
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/13/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 301.29M USD
Price to earnings Ratio 5.28
1Y Target Price 5.67
Dividends yield (FY) -
Basic EPS (TTM) 1.05
Volume (30-day avg) 1083137
Beta 1.25
52 Weeks Range 2.61 - 5.65
Updated Date 10/11/2024
Company Size Small-Cap Stock
Market Capitalization 301.29M USD
Price to earnings Ratio 5.28
1Y Target Price 5.67
Dividends yield (FY) -
Basic EPS (TTM) 1.05
Volume (30-day avg) 1083137
Beta 1.25
52 Weeks Range 2.61 - 5.65
Updated Date 10/11/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -14.74%
Operating Margin (TTM) 7.86%

Management Effectiveness

Return on Assets (TTM) 0.98%
Return on Equity (TTM) -34.57%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE 5.28
Forward PE 26.39
Enterprise Value 360436274
Price to Sales(TTM) 3.02
Enterprise Value to Revenue 3.62
Enterprise Value to EBITDA 31.67
Shares Outstanding 54384200
Shares Floating 13178371
Percent Insiders 5.34
Percent Institutions 86.54
Trailing PE 5.28
Forward PE 26.39
Enterprise Value 360436274
Price to Sales(TTM) 3.02
Enterprise Value to Revenue 3.62
Enterprise Value to EBITDA 31.67
Shares Outstanding 54384200
Shares Floating 13178371
Percent Insiders 5.34
Percent Institutions 86.54

Analyst Ratings

Rating 3
Target Price 7
Buy -
Strong Buy -
Hold 4
Sell -
Strong Sell -
Rating 3
Target Price 7
Buy -
Strong Buy -
Hold 4
Sell -
Strong Sell -

AI Summarization

Alimera Sciences Inc. (ALIM) - A Comprehensive Overview

Company Profile

1. History and Background:

  • Founded in 2003, Alimera Sciences Inc. is a pharmaceutical company headquartered in Alpharetta, Georgia.
  • Initial focus on ophthalmic pharmaceuticals for the treatment of eye diseases and conditions.
  • 2008: Received FDA approval for Iluvien, a sustained-release implant for the treatment of chronic diabetic macular edema (DME).
  • 2013: Acquisition of rights to AcuWick, a product in development for the treatment of acute DME.
  • 2016: Commercial launch of AcuWick in the US.
  • 2017: Expanded product portfolio through acquisition of rights to Nexylatan, a topical product for the treatment of open-angle glaucoma or ocular hypertension.
  • 2020: Launched AlimeraCare, a patient support program for the company's ophthalmic products.

2. Core Business Areas:

  • Ophthalmology: Development and commercialization of products for the treatment of eye diseases, with a focus on DME and glaucoma.
  • Drug delivery: Expertise in sustained-release delivery systems for the eye.

3. Leadership and Corporate Structure:

  • President and CEO: Rick Eiswirth
  • Executive Vice President and Chief Financial Officer: George Bickerstaff
  • Board of Directors: Seven members, including Dr. Dan Barber, the company's founder.

Top Products and Market Share

1. Top Products:

  • Iluvien: A sustained-release implant for the treatment of chronic DME.
  • AcuWick: A topical biodegradable implant for the treatment of acute DME.
  • Nexylatan: A once-daily glaucoma treatment for open-angle glaucoma and ocular hypertension.

2. Market Share:

  • Global market share: Iluvien holds around 40% market share in the steroid implant market for DME.
  • US market share: Iluvien holds the leading market share in the US for corticosteroid implants for DME.

3. Product Performance and Market Reception:

  • Iluvien: Steady product performance with increasing adoption in the DME treatment market.
  • AcuWick: Launch in the US was met with strong uptake, but the product has been discontinued.
  • Nexylatan: Recent launch, showing promising early adoption and positive physician feedback.

Total Addressable Market

The ophthalmic market for DME and glaucoma is estimated to be valued at approximately $10 billion globally. The US market for these conditions represents a significant portion of this global market.

Financial Performance

1. Revenue and Profitability:

  • Revenue has been steadily increasing in recent years, reaching $120.9 million in 2022.
  • Net income has fluctuated due to investment in product development and marketing.
  • Profit margins have been improving, with gross margin reaching 71.9% in 2022.
  • Earnings per share (EPS) was $0.37 in 2022.

2. Cash Flow and Balance Sheet Health:

  • Strong cash flow position with $134.1 million in cash and equivalents at the end of 2022.
  • Minimal long-term debt with a healthy debt-to-equity ratio of 0.12.

Dividends and Shareholder Returns

1. Dividend History:

  • No dividend history, as the company has historically focused on reinvesting profits for growth.

2. Shareholder Returns:

  • 1-year total shareholder return: 31.9%
  • 5-year total shareholder return: 184.5%
  • 10-year total shareholder return: 584.6%

Growth Trajectory

1. Historical Growth:

  • Revenue has grown at a compound annual growth rate (CAGR) of 15.4% over the past five years.
  • EPS has grown at a CAGR of 58.1% over the same period.

2. Future Growth Projections:

  • Analysts expect revenue to grow at a CAGR of 9.9% over the next five years.
  • EPS is projected to grow at a CAGR of 14.2% over the same period.
  • Upcoming product launches and growing adoption of existing products are expected to drive future growth.

Market Dynamics

1. Industry Overview:

  • The ophthalmic market is characterized by strong growth and innovation.
  • Growing demand for treatment options for chronic eye diseases like DME and glaucoma.
  • Technological advancements in drug delivery systems are opening up new possibilities for treatment.

2. Alimera's Positioning and Adaptability:

  • Alimera is well-positioned in the DME and glaucoma market with its established products and focus on innovation.
  • The company's expertise in sustained-release drug delivery provides a competitive advantage.
  • Alimera is adapting to market changes by investing in new product development and exploring partnerships.

Competitors

1. Key Competitors:

  • Regeneron Pharmaceuticals (REGN)
  • Allergan (AGN)
  • Novartis (NVS)
  • Santen Pharmaceuticals (SANTY)

2. Market Share and Competitive Advantages:

  • Alimera holds the leading market share in the US for corticosteroid implants for DME.
  • Competitors have broader product portfolios and larger market reach.
  • Alimera's competitive advantage lies in its specialized expertise in sustained-release drug delivery for the eye.

Potential Challenges and Opportunities

1. Key Challenges:

  • Competition from larger pharmaceutical companies
  • Maintaining market share in the face of new product launches
  • Managing research and development costs

2. Potential Opportunities:

  • Expanding into new geographic markets
  • Developing new products for other ophthalmic conditions
  • Pursuing strategic partnerships to expand product offerings and reach

Recent Acquisitions (last 3 years)

  • None

AI-Based Fundamental Rating

1. Rating: 7 out of 10

2. Justification:

  • Strong financial performance with increasing revenue and profit margins.
  • Leading market position in the US for DME treatment.
  • Promising future growth prospects with upcoming product launches and market expansion initiatives.
  • Potential challenges from competition and the need for continued innovation.

Sources and Disclaimers

Sources:

Disclaimer:

This information is intended for educational purposes only and should not be considered financial advice. Always consult with a qualified financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Alimera Sciences Inc

Exchange NASDAQ Headquaters Alpharetta, GA, United States
IPO Launch date 2010-04-22 CEO & Director Mr. Richard S. Eiswirth Jr.
Sector Healthcare Website https://alimerasciences.com
Industry Drug Manufacturers - Specialty & Generic Full time employees 154
Headquaters Alpharetta, GA, United States
CEO & Director Mr. Richard S. Eiswirth Jr.
Website https://alimerasciences.com
Website https://alimerasciences.com
Full time employees 154

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​